Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Healios KK Ord Shs HLOSF

Healthcare Biotechnology
Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.


PINL:HLOSF - Post by User

Healios KK Ord Shs
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by McLachertyon Nov 14, 2010 4:15pm
233 Views
Post# 17704573

Strong Buy - Barchart.Com

Strong Buy - Barchart.ComHalo Resources Ltd (HLOSF) 0.4611 -0.0339 (-6.85%) Wednesday, Nov 10th, 2010 Detailed Opinion Show Signal Strength and Direction Composite Indicators Signal TrendSpotter Buy Short Term Indicators 7 Day Average Directional Indicator Buy 10 - 8 Day Moving Average Hilo Channel Buy 20 Day Moving Average vs Price Buy 20 - 50 Day MACD Oscillator Buy 20 Day Bollinger Bands Hold Short Term Indicators Average: 80% Buy 20-Day Average Volume - 2,835 Medium Term Indicators 40 Day Commodity Channel Index Hold 50 Day Moving Average vs Price Buy 20 - 100 Day MACD Oscillator Buy 50 Day Parabolic Time/Price Buy Medium Term Indicators Average: 75% Buy 50-Day Average Volume - 24,716 Long Term Indicators 60 Day Commodity Channel Index Buy 100 Day Moving Average vs Price Buy 50 - 100 Day MACD Oscillator Buy Long Term Indicators Average: 100% Buy 100-Day Average Volume - 28,458 Overall Average: 88% Buy Price Support Pivot Point Resistance 0.4611 0.4611 0.4611 0.4611 Click on the indicator for a graphical interpretation, or visit the Education Center for information on the studies.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities